COVID-19 UPDATE: All elective surgeries and procedures are cancelled until further notice. Please see our latest visitor policy. If you think you may have been exposed or have symptoms, please call your provider before visiting one of our locations. For more information, please visit our online COVID-19 Information Center or call the Montefiore-Einstein COVID-19 Hotline: 1-844-444-CV19 (1-844-444-2819).

ACTUALIZACIÓN SOBRE EL COVID-19: Todas las cirugías y operaciones quedan canceladas hasta nuevo aviso. Lea nuestras nuevas normas para visitas. Si cree que podría haber estado en contacto con la enfermedad o si presenta síntomas, por favor llame a su proveedor antes de acudir a cualquiera de nuestros centros. Más información en nuestro Centro de Información en Línea sobre el COVID-19 o llamando a la línea informativa Montefiore-Einstein de COVID-19: 1-844-444-CV19 (1-844-444-2819).

Espanol
Tertiary Hyperparathyroidism
Home >  Cancer (Oncology) >  Diseases and Conditions >  Endocrine/Neuroendocrine Tumors >  Parathyroid Disorders >  Tertiary Hyperparathyroidism
Print

Diseases and Conditions

Tertiary Hyperparathyroidism

Tertiary hyperparathyroidism occurs in patients that have undergone kidney transplantation for kidney failure. These patients have developed secondary hyperparathyroidism prior to receiving the kidney transplant.

Typically, hyperparathyroidism will resolve over the first year following kidney transplantation, as the new kidney can adequately control calcium and phosphorus excretion in the urine and, over time, the parathyroid glands begin to function normally again. In some patients this does not occur and the parathyroid glands continue to function abnormally despite normal kidney function, a condition termed tertiary hyperparathyroidism.

Similarly to treatment for secondary hyperparathyroidism, treatment for tertiary hyperparathyroidism involves removing most of the parathyroid glands. A small portion of parathyroid tissue is preserved to regulate calcium levels following surgery.

The Endocrine and Neuroendocrine Tumor Program treats tertiary hyperparathyroidism using the most advanced technologies and treatments available.